openPR Logo
Press release

Male Hypogonadism Market Growth Contemplation By 2025

04-30-2018 07:08 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: TMR Research

Global Male Hypogonadism Market: Snapshot

Hypogonadism in males refers to a condition in the male body where the testes show a significantly reduced level of functioning than normal. The overall result of male hypogonadism is a reduction in the rate of biosynthesis of male sex hormones. This state is more commonly known as interrupted stage 1 puberty. Hypoandrogenism, or the low androgen or testosterone level in a male can vary in severity from person to person. It is often the cause of partial or complete infertility. There are multiple forms of male hypogonadism and even more ways to classify them. Most endocrinologists commonly classify male hypogonadism on the basis of the level of defectiveness of the male reproductive system.

Request Sample Copy of the Report @
https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1127

In many cases, doctors also measure the level of gonadotropins to classify a patient between primary and secondary male hypogonadism. Primary male hypogonadism refers to the cause of the condition being due to defective gonads. There are different types of primary male hypogonadism, including Turner syndrome and Klinefelter syndrome. Secondary male hypogonadism is caused by defects in pituitary or hypothalamic glands. They include Kallmann syndrome and hypopituitarism.

Global Male Hypogonadism Market: Overview

Male Hypogonadism refers to a clinical condition, wherein the testes fail to produce enough testosterone leading to delayed puberty or incomplete development. The condition is related to impaired development of muscle mass, development of breast tissues, impaired body hair growth, and lack of deepening of the voice.

The male Hypogonadism market can be segmented by therapy, type, drug delivery, and geography.

The report presents an in-depth analysis of the global male hypogonadism market with current trends and future estimates to explain the imminent investment pockets. The quantitative analysis of the market for the forecast period from 2017 to 2025 will enable stakeholders to capitalize on the prevailing growth opportunities.

Global Male Hypogonadism Market: Trends and Opportunities

The top driver of the male hypogonadism market includes rising prevalence of testosterone deficiency among men, increasing infertility rates, and increasing awareness among individuals about hypogonadism treatment due to awareness drives organized by several governments across the world. Moreover, high risk of hypogonadism among the geriatric population with obesity and diabetes, and increasing prevalence of chronic disorders among the geriatrics are further expected to boost the market’s growth.

Request TOC of the Report @
https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1127

However, factors such as high side effects of testosterone products are challenging the growth of testosterone replacement therapy market. Top players in the market are focused on research and development to introduce newer products with fewer or negligible side effects and improved results. For example, LPCN 1111, a product which is under development from Lipocine Inc., is a newer testosterone prodrug that utilizes Lip’ral technology for enhanced systemic absorption and for enhanced solubility of testosterone. Nevertheless, technological advancements are anticipated to extend new opportunities to the market’s growth.

Global Male Hypogonadism Market: Regional Overview

The global male Hypogonadism market can be analyzed with respect to the regional segments of North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. North America held the majority share of the global market in the recent past and is expected to retain its dominant position in the near future. This is mainly due to the rise in the number of individuals suffering from primary and secondary conditions of hypogonadism, and rising awareness among individuals about treatment options for the condition. Moreover, the presence of ultra-modern healthcare infrastructure and increasing popularity of technologically advanced products are expected to offer new opportunities for top players in this market. The region is closely followed by Europe.

Asia Pacific is expected to offer lucrative opportunities to this market due to the modernization of the healthcare infrastructure in the emerging economies of India and China and the increasing awareness about the treatment for the condition. In Asia Pacific, the increasing prevalence of hypogonadism and infertility rates along with the rising geriatric population base with diabetes and obesity are propelling the growth of this market. China, Taiwan, and Malaysia are some of the countries that display the highest rate of male hypogonadism.

Read Comprehensive Overview of Report @
https://www.tmrresearch.com/male-hypogonadism-market

Major Companies Mentioned in Report

Some of the key players in the male Hypogonadism market include AbbVie Inc., Astrazeneca plc, Eli Lilly and Company Ltd., Merck & Co. Inc., SA, Finox Biotech, Laboratories Genevrier, Teva Pharmaceutical Industries Ltd., Allergan plc, Bayer AG, Endo International plc, IBSA Institut Biochimque, and Ferring.

Key players are focused on product approval for growth considerations and to cater to the changing demand of the industry. The introduction of innovative and technologically advanced products is also the focus of key players to increase their market share and for serving patients in a better manner.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Email: sales@tmrresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Male Hypogonadism Market Growth Contemplation By 2025 here

News-ID: 1034074 • Views: 486

More Releases from TMR Research

Electric Enclosure Market Analysis Growth Demand, Key Players, Share Size, and F …
Electric enclosure is a cabinet used for protecting the electrical components such as transformers, generators and also to cover switches, knobs, and displays to prevent electric shocks. In the renewable energy industries, the electric enclosures are in high demand. Many other factors such as growing awareness regarding safety and escalating cost of industrial maintenance operations are also creating sustained opportunities for players. Moreover, development of IOT-based enclosures are on a surge
Spray Hair Dye Market Current Trends and Future Aspect Analysis 2019 - 2029 | L …
Spray Hair Dye Market Outlook In the present era, the hair colorant industry is currently under significant growth to develop natural and economic spray hair dyes. As most of the conventional hair dye contains ammonia, peroxide, and other oxidizing agents which may cause hair loss and ultimately leads to unhealthy hair. Moreover, the chemicals used in hair dye may change the entire biological composition of the hair- causing allergies and irritation
Tennis Equipment Market Share and Growth Factors Impact Analysis 2019 - 2029 | Y …
Global Tennis Equipment Market: Overview The demand within the global tennis equipment market is expected to grow at a stellar pace in the times to follow. Commercialization of sports has generated humongous revenues across multiple nations and economies. It is imperative for the market players to decode the propensities of tennis tournaments and players to tap into the market. Tennis has grown as a sport across several new territories, creating fresh
Contact Center Software Market Development and Opportunities with Forecast 2028
Global Contact Center Software Market: Snapshot The global contact center software market is prognosticated to gain from the rising demand in a number of industry verticals. However, there could be rapid growth of the global contact center software market witnessed in retail and consumer goods. Professional and managed are the two main types of services offered in the global contact center software market. Improvement in technology is expected to play a

All 5 Releases


More Releases for Hypogonadism

Male Hypogonadism: North America to Remain Largest Market for Male Hypogonadism …
The report "Global Market Study on Male Hypogonadism: North America to Remain Largest Market for Male Hypogonadism during 2017 - 2026 ", has been prepared based on an in-depth market analysis with inputs from industry experts. Male hypogonadism is a condition in males wherein the testes depict a significantly reduced functioning level than normal. Reduction in rate of biosynthesis of the male sex hormones consequently results into male hypogonadism, which can
Male Hypogonadism Market Poised to Reach $ 3,300 Mn by 2026
North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market.
Male Hypogonadism Market Growth Bar Increases $3,233 Million In 2022
Male hypogonadism is a medical condition characterized by the inability of the testes to produce sufficient amount of testosterone, which is responsible for the development of secondary sexual characteristics. This results in underdevelopment of muscles, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice. For More Info, Get Sample : http://bit.ly/2Day9tu The global male hypogonadism market was valued at $2,594 million in
Male Hypogonadism - Pipeline Review, H1 2017
ReportsWeb.com has announced the addition of the “Male Hypogonadism - Pipeline Review, H1 20172017” The report focuses on global major leading industry players with information such as company profiles, product picture and specification. Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann
Male Hypogonadism - Pipeline Review, H2 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Male Hypogonadism - Pipeline Review, H2 2017”. Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Request For Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1246563 Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and
NH Therapeutics receives orphan drug designation for congenital hypogonadotropic …
NH Therapeutics, a biopharmaceutical company that focuses on developing drugs and therapies for effective treatment of rare neuroendocrine disorders, recently announced that European Medicine Agency has awarded its leading drug candidate NH-901 with orphan drug designation for the treatment of congenital hypogonadotropic hypogonadism. NH901 is a reformulation of a GnRH analogue, which has been repurposed to increase gonadotropins, sex hormones and boost fertility. The Stichting Centre for Human Drug Research